Dr. Steven Pipe, Pediatric Medical Director of the Hemophilia and Coagulation Disorders Program in Ann Arbor Michigan, presented an update at the World Federation of...
The global bleeding disorder community received an advance look at new international guidelines for the management of hemophilia at the WFH Virtual Summit 2020, at...
The development of inhibitory antibodies to therapeutic FVIII in up to 40% of severe hemophilia A (HA) patients is a major complication in the treatment...
In this session, three “hot topics” related to muscle, bone and joint health in people with bleeding disorders were debated by experts in their fields:...
Toronto, July 22, 2020 – Ferring Pharmaceuticals has discontinued production of OCTOSTIM SPRAY (150 mpg DIN 02237860) for the treatment of mild and moderate hemophilia A...
